within Pharmacolibrary.Drugs.ATC.L;

model L01EB09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.56,
    Cl             = 0.23,
    adminDuration  = 600,
    adminMass      = 0.24,
    adminCount     = 1,
    Vd             = 0.426,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00735,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Lazertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). It selectively targets both EGFR activating and T790M resistance mutations while sparing wild-type EGFR, thereby reducing off-target effects. Lazertinib is approved for clinical use in South Korea and has ongoing studies elsewhere.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with advanced EGFR mutation-positive NSCLC following single and multiple oral dosing. The parameters are generally for healthy adults or cancer patients (no specific restrictions on age or sex).</p><h4>References</h4><ol><li><p>Ahn, MJ, et al., &amp; Cho, BC (2019). Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. <i>The Lancet. Oncology</i> 20(12) 1681–1690. DOI:<a href=&quot;https://doi.org/10.1016/S1470-2045(19)30504-2&quot;>10.1016/S1470-2045(19)30504-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31587882/&quot;>https://pubmed.ncbi.nlm.nih.gov/31587882</a></p></li><li><p>Huh, KY, et al., &amp; Yu, KS (2023). Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer. <i>Lung cancer (Amsterdam, Netherlands)</i> 175 112–120. DOI:<a href=&quot;https://doi.org/10.1016/j.lungcan.2022.11.021&quot;>10.1016/j.lungcan.2022.11.021</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36495784/&quot;>https://pubmed.ncbi.nlm.nih.gov/36495784</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EB09;
